Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 8/20 | 0.41 |
| ▸ | AR | P10275 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.37 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.37 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | DHODH | Q02127 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | RORC | P51449 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18178410 | 0.93 | MRGPRX4 (0.43) | MRGPRX4RORC | |
| SCHEMBL18178309 | 0.92 | MRGPRX4 (0.42) | MRGPRX4SMN1; SMN2ALDH1A1RAB9ARORC | |
| SCHEMBL18178215 | 0.91 | MRGPRX4 (0.39) | MRGPRX4SGMS2RAB9AMAPTRORC | |
| SCHEMBL18178214 | 0.91 | MRGPRX4 (0.39) | MRGPRX4 | |
| SCHEMBL18178615 | 0.90 | MAPT (0.38) | MRGPRX4ARALDH1A1POLBRAB9A | |
| SCHEMBL18182833 | 0.90 | MRGPRX4 (0.41) | MRGPRX4ARSMN1; SMN2SGMS2ALDH1A1 | |
| SCHEMBL18178169 | 0.88 | MRGPRX4 (0.40) | MRGPRX4SMN1; SMN2SGMS2ALDH1A1POLB | |
| SCHEMBL18178145 | 0.88 | DHODH (0.40) | MRGPRX4SMN1; SMN2SGMS2ALDH1A1POLB | |
| SCHEMBL18178179 | 0.88 | MRGPRX4 (0.42) | MRGPRX4SMN1; SMN2SGMS2ALDH1A1POLB | |
| SCHEMBL18178218 | 0.88 | MRGPRX4 (0.38) | MRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9573904-B2 | Aromatic compound and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-02-21 | — | — | US | disclosed |
| US-20160311775-A1 | AROMATIC COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160311775-A1 | AROMATIC COMPOUND AND USE THEREOF | ZCCHC8, CBR3, CBX8 | MRGPRX4 167/4885AR 783/4885SMN1; SMN2 4166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.